Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Metastatic Hormone Refractory Prostate Cancer 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 344Cytarabine 281fludarabine phosphate 201Methotrexate 185Filgrastim 159Busulfan 147Etoposide 135Peripheral Blood Stem Cell Transplantation 133fludarabine 127Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 85Mycophenolic Acid 85Whole-Body Irradiation 80Melphalan 79Idarubicin 67Mercaptopurine 66Imatinib Mesylate 66Granulocyte Colony-Stimulating Factor 65Azacitidine 65Methylprednisolone 59Prednisone 58Doxorubicin 58Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Leukemia × danusertib × Clear all
NCT00335868 2013-12-18

PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

National Cancer Institute (NCI)

Phase 2 Unknown
16 enrolled
Other hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡